A study evaluating the utility of novel imaging biomarkers (radiomics) to distinguish patients with stage 3 NSCLC may be able to predict who will benefit from treatment from those likely to progress despite therapy. This study was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held virtually 4-10 June, 2021 [1]. Physician’s Weekly spoke with presenter and researcher Dr. Khalid Jazieh, Cleveland Clinic, Ohio.